



NSGO-CTU

Nordic Society of Gynaecological Oncology - Clinical Trial Unit

Agenda (draft) v.1.4

NSGO-CTU Investigator Meeting

7th – 8th December 2023

Copenhagen, Denmark

Scandic Kødbyen Skelbækgade 3A

1717 Copenhagen V



Wednesday 6. December 2023

13:00-14:15 **NSGO-CTU Foundation Meeting** (Closed meeting)

Meeting Room 10 + 11

14:30-15:45 **NSGO Board Meeting** (Closed meeting)

Meeting Room 10 + 11

16:00-17:30 **NSGO-CTU Scientific Committee Meeting** (Closed meeting)

Meeting Room 10 + 11

18:00-19:00 **Dinner** (Closed Dinner for NSGO BOARD -, NSGO-CTU Foundation -, NSGO-CTU Scientific Committee Members and NSGO-CTU Office Staff)

Restaurant Mør

Thursday 7. December 2023

08:30-09:30 Registration & Exhibition

Foyer & Ballroom 3

09:30-09:50 Welcome by Medical Director

Future plans and status report of NSGO-CTU activities

Ballroom 1 + 2 **Mansoor Raza Mirza**

09:50-09:55 Cervical Cancer

Introduction to the Session

Ballroom 1 + 2 **Chairs: Maria Bjurberg and Kristine Madsen**

09:55-10:50 Cervical Cancer Trials

Ballroom 1 + 2

09:55-10:02 ENGOT-CX11/KEYNOTE-A18

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer

Domenica Lorusso

10:02-10:09 ENGOT-CX10/BEATcc

A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent or Recurrent Carcinoma of the Cervix

Ana Oaknin

10:09-10:16 ENGOT-CX8/GCT1015-05

Randomized, open label, phase 1b/2 first line trial with Tisotumab Vedotin

Kristine Madsen

10:16-10:23 ENGOT-CX12/SGNTV003

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice

Chemotherapy in Second- or Third-Line
Recurrent or Metastatic Cervical Cancer

Maria Bjurberg

10:23-10:30 ENGOT-CX19/eVOLVE

Randomized Phase 2/3 Trial of Volrustomig vs. placebo for patients with FIGO stage IIIC-IVA cervical cancer who have completed, and not progressed, following SOC CCRT (≥ 4 cycles)

Trine Jakobi Nøttrup

10:30-10:37 ENGOT-CX20

MK-2870 in cervical cancer

Kristina Lindemann

10:37-10:50 Discussion

Domenica Lorusso

Ana Oaknin

Trine Jakobi Nøttrup

Kristina Lindemann

Sakari Hietanen

Tone Jensen

Kristina Hellmann

10:50-11:15 Break & Exhibition

Ballroom 3

11:15-14:00 NSGO-CTU Scientific Satellite Symposium incl. Lunch

Endometrial Cancer Management in the Era of Immunotherapy

Ballroom 1 + 2

Chairs: Line Bjørge and Henrik Roed

Educational Grant Provided by GSK

**11:20-11.45 50 Years of Management of
Endometrial Cancer**

TBA

**11:45-12.10 Immunotherapy in Endometrial
Cancer**

Ana Oaknin

12:10-12.45 Management of Immune-related Toxicity

Domenica Lorusso

12:45-13.00 Discussion

TBA

Ana Oaknin

Domenica Lorusso

13:00-14.00 Symposium Lunch

Restaurant Mør

14:00-14:05 Endometrial Cancer

Introduction to the Session

Ballroom 1 + 2

Chairs: Trine Jakobi Nøttrup and Gabriel Lindahl

14:05-15:10 Endometrial Cancer: Neoadjuvant, First - and Second Line Trials inkl. Maintenance

Ballroom 1 + 2

14:05-14:12 PELENEO (Neoadjuvant)

A phase II clinical trial investigating pembrolizumab and lenvatinib in neoadjuvant treatment of advanced endometrial cancer

Kristina Lindemann

14:12-14:19 ENGOT-EN11

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination with Adjuvant Chemotherapy with or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery with Curative Intent

Trine Lembrecht Jørgensen

14:19-14:26 ENGOT-EN6/RUBY part 1+2

A Phase 3 Randomized Open-Label Study of TSR-042, an anti-PD-1 Mono-clonal Antibody, Versus Investigator's Choice Chemotherapy in Advanced/Recurrent Endometrial Cancer

Gabriel Lindahl

14:26-14:33 ENGOT-EN10/DUO-E

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-Line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer

[Goda Jonuskiene](#)

14:33-14:40 ENGOT-EN15/KEYNOTE-C93

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting

[Heini Lassus](#)

14:40-14:47 ENGOT-EN24/DESTINY

[Mansoor Raza Mirza](#)

14:47-14:55 ENGOT-EN21

A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with *TP53WT* Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy

[Kristiina Ojamaa](#)

14.55-15.02 ENGOT-EN23 (2nd line)

A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Immunotherapy

[Ingvild Vistad](#)

15.02-15.25 Discussion

[Kristina Lindemann](#)

[Trine Lembrecht Jørgensen](#)

[Goda Jonuskiene](#)

[Heini Lassus](#)

[Mansoor Raza Mirza](#)

Kristiina Ojamaa
Ingvild Vistad
Katharina Bischof
Karin Grisan

15:25-17:00 Break & Exhibition

Ballroom 3

17:00-20:30 NSGO-CTU Scientific Satellite Symposium incl. Dinner

Novel First Line Therapies in Ovarian Cancer

Ballroom 1 + 2 **Chairs: Anniina Färkkilä and Mansoor Raza Mirza**

Educational Grant Provided by AstraZeneca

**17:00-17.30 Bevacizumab and PARP-inhibitors
in Combination with
Immunotherapy:
Challenges/Missing Information in
Trial Design and Interpretation of
Results**

Nicoletta Colombo

**17:30-18.00 Current Maintenance Therapy
Approach in First Line Treatment**

Isabelle Ray-Coquard

**18:00-18.30 The Role of Immunotherapy in
Ovarian Cancer**

Philipp Harter

18:30-19.00 Discussion

Nicoletta Colombo

Isabelle Ray-Coquard

Philipp Harter

19:00-20.30 Symposium Dinner

Restaurant Mør

Please evaluate the day by scanning the QR code with your mobile camera and open the link



Friday 8. December 2023

08:15-08:20 Ovarian Cancer: Surgical Trials

Ballroom 1 + 2

Introduction to the Session

Chairs: Ane Gerda Zahl Eriksson and Marta Lomnytsky

08:20-08:40 Primary Surgery and HIPEC

Ballroom 1 + 2

08:20-08:27 OVHIPEC-2

Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy

Berit Jul Mosgaard

08:27-08:40 Discussion

Berit Jul Mosgaard

Tine Henrichsen-Schnack

08.40-08.45 Ovarian Cancer: First Line Trials

Ballroom 1 + 2

Introduction to the Session

Chairs: Anniina Färkkilä and Jørn Herrstedt

08:45-09:10 First Line Maintenance Therapy with Bevacizumab/PARP-i

Ballroom 1 + 2

08:45-08:52 ENGOT-OV25/PAOLA-1

Randomised, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Cancer, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance

Sakari Hietanen

08:52-08:59 ENGOT-OV26/PRIMA

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced

Ovarian Cancer Following Response on Front-Line
Platinum-Based Chemotherapy

[Nicoline Raaschou-Jensen](#)

08:59-09:10 Discussion

[Sakari Hietanen](#)

[Nicoline Raaschou-Jensen](#)

[Jenni Lifjeld](#)

[Maarit Anttila](#)

09:10-09:55 Immunotherapy as First Line Treatment

Ballroom 1 + 2

09:10-09:17 ENGOT-OV44/FIRST

An adaptive Randomized Phase III Comparison of Standard Platinum Based Treatment Versus Platinum and TSR-042 followed by Niraparib and TSR-042 maintenance Therapy in Patients with epithelial Stage III or IV Cancer of the Ovary, Fallopian Tube, or Peritoneum

[Jørn Herrstedt](#)

09:17-09:24 ENGOT-OV46/DUO-0

Phase III Randomized, Double Blind, Placebo Controlled, Multicentre Study of durvalumab in combination with chemotherapy and bevacizumab followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer patients

[Henna Kärkkäinen](#)

09:24-09:33 ENGOT-OV45/ATHENA

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment following Response to Front-Line Platinum-Based Chemotherapy

[Josefin Fernebro](#)

09:33-09:55 Discussion

[Henna Kärkkäinen](#)

[Josefin Fernebro](#)

[Bente Vilming](#)

[Asgeir Thoroddsen](#)

09:55–10:30 Break & Exhibition*Ballroom 3***10:30–11:30 Ovarian Cancer: Platinum is an Option & Maintenance***Ballroom 1 + 2***Chairs: [Hanna Dahlstrand](#) and [Birute Brasiuniene](#)****10:30–10:46 ENGOT-OV56/DOVACC**

A Randomized Clinical Trial Investigating Olaparib, Durvalumab and UV1 as Maintenance Therapy in BRCAwt Patients with Relapsed Ovarian Cancer

[Susanne Malander](#)**10:46–10:53 KANDOVA**

A two-part Phase Ib/IIa study to evaluate the safety and tolerability of KAND567 in combination with carboplatin therapy and to determine the Recommended Phase II Dose (RPIID). An open-label, multicenter dose escalation study with an expansion cohort in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

[Hanna Dahlstrand](#)**10:53–11:10 Discussion****[Susanne Malander](#)****[Maria Dimoula](#)****[Trine Stokstad](#)****[Katrín Kristjansdóttir](#)****11:10–12:30 Ovarian Cancer: Platinum is Not an Option and Palliation***Ballroom 1 + 2***Chairs: [Kristina Lindemann](#) and [Susanne Malander](#)****11:10–11:17 ENGOT-OV65 (MSD)**

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

[Anne Marie Hansson](#)**11:17–11:24 ENGOT-OV68/ARTISTRY-7**

A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

[Birute Brasiuniene](#)

11:24-11:31 DS6000

Randomized Phase 2/3 Trial of DS-6000 in platinum-resistant ovarian cancer

[Elisabeth Berge Nilsen](#)

11:31-11:38 ENGOT-OV-79/REFRaME-01

Randomized phase 2/3 Study of Luvelta vs. Standard Chemotherapy in Platinum Resistant Ovarian Cancer

[Trine Zeeberg Iversen](#)

11:38-11:45 EPIK-O

A Phase III, multi-center, randomized (1:1), openlabel, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer

[Annika Auranen](#)

11:45-11:52 PEACE

Palliation in gynae-oncology: Evaluation and Assessment of satisfaction with care

[Kristina Lindemann](#)

11:52-12:15 Discussion

[Anne Marie Hansson](#)

[Birute Brasiuniene](#)

[Elisabeth Berge Nilsen](#)

[Trine Zeeberg Iversen](#)

[Annika Auranen](#)

[Goda Jonuskiene](#)

[Ulrika Joneborg](#)

[Jone Trovik](#)

12:15-13:15 Lunch

Restaurant MØR

13:15-15:10 Translational Research Session

Chair(s): [Line Bjørge](#)

Ballroom 1 + 2

TBA TBA

15:10-15:15 Closing Remarks

Line Bjørge

Ballroom 1 + 2

Please evaluate the day and the meeting in general by scanning the below QR codes with your mobile camera and open the link



This Meeting is Sponsored by